Detalhe da pesquisa
1.
Combined Lanreotide Autogel and Temozolomide Treatment of Progressive Pancreatic and Intestinal Neuroendocrine Tumors: The Phase II SONNET Study.
Oncologist
; 29(5): e643-e654, 2024 May 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-38206830
2.
Hemicolectomy versus appendectomy for patients with appendiceal neuroendocrine tumours 1-2 cm in size: a retrospective, Europe-wide, pooled cohort study.
Lancet Oncol
; 24(2): 187-194, 2023 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-36640790
3.
Clinical characteristics, treatment patterns, and persistence in individuals with type 2 diabetes initiating a glucagon-like peptide-1 receptor agonist: A retrospective analysis of the Diabetes Prospective Follow-Up Registry.
Diabetes Obes Metab
; 25(7): 1813-1822, 2023 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-36855221
4.
Response heterogeneity as a new biomarker of treatment response in patients with neuroendocrine tumors.
Future Oncol
; 19(32): 2171-2183, 2023 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-37497626
5.
The use of deep learning models to predict progression-free survival in patients with neuroendocrine tumors.
Future Oncol
; 19(32): 2185-2199, 2023 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-37497644
6.
DLL3 as an Emerging Target for the Treatment of Neuroendocrine Neoplasms.
Oncologist
; 27(11): 940-951, 2022 11 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-35983951
7.
Streptozotocin, 1982-2022: Forty Years from the FDA's Approval to Treat Pancreatic Neuroendocrine Tumors.
Neuroendocrinology
; 112(12): 1155-1167, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-35537416
8.
Long-Term Treatment with Telotristat Ethyl in Patients with Carcinoid Syndrome Symptoms: Results from the TELEPATH Study.
Neuroendocrinology
; 112(3): 298-310, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-33940581
9.
[Treatment strategy by radioiodine refractory differentiated thyroid cancer]. / Behandlungsstrategie beim radiojodrefraktären differenzierten Schilddrüsenkarzinom.
Laryngorhinootologie
; 101(4): 298-303, 2022 Apr.
Artigo
em Alemão
| MEDLINE | ID: mdl-34583388
10.
Treatment of advanced gastroenteropancreatic neuroendocrine neoplasia, are we on the way to personalised medicine?
Gut
; 70(9): 1768-1781, 2021 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-33692095
11.
177Lu-Dotatate plus long-acting octreotide versus highdose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial.
Lancet Oncol
; 22(12): 1752-1763, 2021 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-34793718
12.
Relationship between metabolic toxicity and efficacy of everolimus in patients with neuroendocrine tumors: A pooled analysis from the randomized, phase 3 RADIANT-3 and RADIANT-4 trials.
Cancer
; 127(15): 2674-2682, 2021 08 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33857327
13.
Tumor Growth Rate to Predict the Outcome of Patients with Neuroendocrine Tumors: Performance and Sources of Variability.
Neuroendocrinology
; 111(9): 831-839, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-32717738
14.
Multiple Endocrine Neoplasia Type 1 and the Pancreas: Diagnosis and Treatment of Functioning and Non-Functioning Pancreatic and Duodenal Neuroendocrine Neoplasia within the MEN1 Syndrome - An International Consensus Statement.
Neuroendocrinology
; 111(7): 609-630, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-32971521
15.
Antiproliferative Systemic Therapies for Metastatic Small Bowel Neuroendocrine Tumours.
Curr Treat Options Oncol
; 22(8): 73, 2021 06 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-34185197
16.
Everolimus-induced pneumonitis in neuroendocrine neoplasms: correlation of CT findings and clinical signs.
Acta Radiol
; 62(8): 1006-1015, 2021 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-32819165
17.
Matching-adjusted indirect treatment comparison of [177Lu]Lu-DOTA-TATE, everolimus and sunitinib in advanced, unresectable gastroenteropancreatic neuroendocrine tumours: Relative effectiveness of [177Lu]Lu-DOTA-TATE in gastroenteropancreatic neuroendocrine tumours.
EJC Suppl
; 16: 5-13, 2021 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-34912478
18.
Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors.
N Engl J Med
; 376(2): 125-135, 2017 01 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-28076709
19.
Surgery with Radical Intent: Is There an Indication for G3 Neuroendocrine Neoplasms?
Ann Surg Oncol
; 27(5): 1348-1355, 2020 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-31720931
20.
Prognostic Significance of Somatostatin Receptor Heterogeneity in Progressive Neuroendocrine Tumor Treated with Lu-177 DOTATOC or Lu-177 DOTATATE.
Eur J Nucl Med Mol Imaging
; 47(4): 881-894, 2020 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-31414209